Medication leaflets

Active substance

Results for the substance turoctocog alfa

6 results

About this active substance

Turoctocog alfa is a recombinant factor VIII used for the treatment and prevention of bleeding episodes in patients with hemophilia A, a genetic disorder characterized by a deficiency of factor VIII. This medication is essential for controlling bleeding and preventing complications associated with hemophilia.

Turoctocog alfa is administered intravenously, with the dosage adjusted based on the severity of hemophilia, the location and severity of the bleeding, and the patient's body weight. It is used for both the treatment of acute bleeding episodes and long-term prophylaxis.

Common side effects include injection site reactions, headache, and fever. In rare cases, patients may develop inhibitors to factor VIII, which reduces the effectiveness of the treatment. Regular monitoring is essential to evaluate the response to treatment and adjust the dosage if necessary.

Turoctocog alfa is a safe and effective therapeutic option for patients with hemophilia A, helping to improve their quality of life and prevent severe bleeding complications.